Literature DB >> 28403505

The Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Biliary Atresia: 14 Years' Experience.

Ahmed A Negm1, Claus Petersen2, Andrea Markowski1, Birgit Luettig1, Kristina I Ringe3, Tim O Lankisch1, Michael P Manns1, Benno Ure2, Andrea S Schneider1.   

Abstract

INTRODUCTION: Biliary atresia (BA) is a rare destructive inflammatory obliterative cholangiopathy of neonates. Early diagnosis is important in disease management. The aim was to evaluate the role of endoscopic retrograde cholangiopancreatography (ERCP) in diagnosing BA in a large cohort. In addition, we evaluated whether parameters such as bile trace, GGT, bilirubin, and laboratory values in combination can be used to develop a risk score that could indicate the referral to specialized centers.
MATERIALS AND METHODS: All infants with neonatal cholestasis (2000-2014) who presented to our endoscopy unit for suspected BA were included. Demographics, laboratory parameters, ultrasound findings, liver biopsy results, ERCP diagnosis, and surgical outcome were collected. Value and safety of ERCP and risk factors for BA were retrospectively analyzed.
RESULTS: We included 251 infants in our cohort (55% males, median age: 53 days). BA was intraoperatively diagnosed in 155 (83.4%) patients and was excluded in 30 (16.2%). Fifty-six cases were not operated due to the ERCP findings. ERCP was successful in 224/251 patients (89.2%) with no procedure-related complications. The operative and endoscopic diagnosis matched in 96.6% of the patients (positive predictive value: 92.2%, negative predictive value: 97.1%). In comparison to cases with excluded BA, the ones with this disease were significantly associated with absence of duodenal bile traces (98.4 vs. 1.6%, p < 0.001), higher bilirubin (p < 0.001, cutoff 7.3 mg/dL), and higher GGT (p < 0.001, cutoff 250 U/L).
CONCLUSION: ERCP is safe and accurate in the hands of experts in diagnosing BA if the cause of cholestasis is unclear. While evaluating the role of ERCP for diagnosing this disease, we found that the secondary parameters GGT > 250 U/L, bilirubin > 7.3 mg/dL (125 μmol/L), and the absence of bile traces are risk factors. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28403505     DOI: 10.1055/s-0037-1602260

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  4 in total

1.  Practical approach for the diagnosis of biliary atresia on imaging, part 2: magnetic resonance cholecystopancreatography, hepatobiliary scintigraphy, percutaneous cholecysto-cholangiography, endoscopic retrograde cholangiopancreatography, percutaneous liver biopsy, risk scores and decisional flowchart.

Authors:  Marcello Napolitano; Stéphanie Franchi-Abella; Beatrice Maria Damasio; Thomas Angell Augdal; Fred Efraim Avni; Costanza Bruno; Kassa Darge; Damjana Ključevšek; Annemieke Simone Littooij; Luisa Lobo; Hans-Joachim Mentzel; Michael Riccabona; Samuel Stafrace; Seema Toso; Magdalena Maria Woźniak; Giovanni Di Leo; Francesco Sardanelli; Lil-Sofie Ording Müller; Philippe Petit
Journal:  Pediatr Radiol       Date:  2021-05-11

Review 2.  Biliary atresia and congenital disorders of the extrahepatic bile ducts.

Authors:  Ali Islek; Gokhan Tumgor
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-07-05

Review 3.  Recent advances in understanding biliary atresia.

Authors:  Andrew Wehrman; Orith Waisbourd-Zinman; Rebecca G Wells
Journal:  F1000Res       Date:  2019-02-25

4.  Hepatic Subcapsular Flow as a Significant Diagnostic Marker for Biliary Atresia: A Meta-Analysis.

Authors:  Chao Sun; Bin Wu; Jiang Pan; Lulu Chen; Wenxian Zhi; Ruze Tang; Dongliang Zhao; Wanliang Guo; Jian Wang; Shungen Huang
Journal:  Dis Markers       Date:  2020-03-01       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.